Literature DB >> 1979743

Immunological and serological markers predictive of progression to AIDS in a cohort of HIV-infected drug users.

E Fernández-Cruz1, M Desco, M Garcia Montes, N Longo, B Gonzalez, J M Zabay.   

Abstract

We have performed a prospective 33-month follow-up of the evolution of HIV infection in a cohort of 76 HIV-positive intravenous drug users (IVDUs). We report on immunological and serological variables that proved to be highly predictive of development to AIDS. In a stepwise multivariate analysis of the actuarial progression rate we found the number of CD4+ lymphocytes to be the most powerful predictor of progression to AIDS. We found no independent predictive effects associated with any other variable with predictive power: loss of antibody to p24 antigen, anergy, HIV p24 antigenaemia, loss of antibody to p53 (reverse transcriptase), decreased number of CD8+ T cells, loss of antibody to p31, loss of antibody to p17, beta 2-microglobulin level, loss of antibodies to gp41 and p64, or immunoglobulin A level. We have found that our data differ from those obtained in studies in homosexual men in the different prognostic value of those predictive markers. Our findings should help to identify high risk of progression to clinical AIDS among IVDUs, thereby assisting in the selection of patients for prophylaxis and therapy.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1979743     DOI: 10.1097/00002030-199010000-00007

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  10 in total

Review 1.  Clinical and immunological assessment of HIV infection.

Authors:  A G Bird
Journal:  J Clin Pathol       Date:  1992-10       Impact factor: 3.411

2.  Surrogate markers now provide physicians with the best means to manage antiretroviral therapy: the case for.

Authors:  G J Moyle; B G Gazzard; T Peto
Journal:  Genitourin Med       Date:  1997-06

3.  Improving the prognostic value of CD4+ count using IgA and clinical signs in HIV-seropositive i.v. drug users.

Authors:  F Montella; P Pezzotti; F Di Sora; O Recchia; F Lauria; G Rezza
Journal:  Infection       Date:  1997 Mar-Apr       Impact factor: 3.553

4.  Predictors of survival in human immunodeficiency virus type 1-seropositive intravenous drug users.

Authors:  J B Page; S Lai; M A Fletcher; R Patarca; P C Smith; H C Lai; N G Klimas
Journal:  Clin Diagn Lab Immunol       Date:  1996-01

5.  Mechanisms of Host Resistance Against HIV Infection and Progression to AIDS.

Authors:  Ali A Al-Jabri
Journal:  Sultan Qaboos Univ Med J       Date:  2007-08

Review 6.  Clinical aspects of HIV infection in women.

Authors:  G O Coodley; M K Coodley; A F Thompson
Journal:  J Gen Intern Med       Date:  1995-02       Impact factor: 5.128

7.  Slow progression to AIDS in intravenous drug users infected with HIV in Norway.

Authors:  A Eskild; P Magnus; C Sohlberg; P Kittelsen; J H Olving; B Teige; K Skullerud
Journal:  J Epidemiol Community Health       Date:  1994-08       Impact factor: 3.710

8.  Quantification of low levels of human immunodeficiency virus (HIV) type 1 RNA in P24 antigen-negative, asymptomatic, HIV-positive patients by PCR.

Authors:  M A Muñoz-Fernández; J Navarro; M G Montes; J Cosín; J M Zabay; E Fernández-Cruz
Journal:  J Clin Microbiol       Date:  1996-02       Impact factor: 5.948

9.  AIDS-free survival and overall survival in HIV infection: the new CDC classification system (1993) for HIV disease and AIDS.

Authors:  B S Kamps; H R Brodt; S Staszewski; L Bergmann; E B Helm
Journal:  Clin Investig       Date:  1994-03

Review 10.  Isotype Diversification of IgG Antibodies to HIV Gag Proteins as a Therapeutic Vaccination Strategy for HIV Infection.

Authors:  Martyn A French; Laila N Abudulai; Sonia Fernandez
Journal:  Vaccines (Basel)       Date:  2013-08-09
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.